Skip to content
Market MoodExtreme Fear11
Market Cap: $2.22T −2.43%24h Vol: $76.90BBTC: $64,715 +0.23%
NewsMarketsBitcoinEthereumAltcoinsAsiaWeb3EventsAbout Us
LanguageENRU
Subscribe Pro
Markets

SELLAS Life Sciences Shares Surge Over 200% After AML Vaccine Trial Success

SELLAS Life Sciences’ stock jumped more than 200% after Phase 3 trial of its leukemia vaccine met primary endpoint, boosting expectations for 2027 FDA approval.

· 2 min read
smartphone calculator on desk with financial charts behind
Photo by Jakub Żerdzicki on Unsplash

Key takeaways

  • SLS stock rose over 200% after positive Phase 3 results
  • The trial showed a 41% reduction in death risk for AML patients
  • SELLAS plans to discuss accelerated filing with the FDA in 2027

SELLAS Life Sciences (SLS) announced that its Phase 3 REGAL trial of the galinpepimut‑S (GPS) leukemia vaccine achieved its primary endpoint, reporting a 41% reduction in the risk of death among patients with acute myeloid leukemia (AML). The positive topline data triggered a sharp rally, sending the stock above $20 and reaching an intraday high near $25 on November 17, 2026. Investors reacted to the clinical milestone, which could pave the way for accelerated FDA review and a Biologics License Application (BLA) filing in the first half of 2027. The company’s shares are now among the largest gainers in the market, with the price increase exceeding 200% from the previous close.

BitcoinBTC · 24h
$64,715+0.23%

Clinical Impact and Trial Details

The REGAL study enrolled patients who had achieved a second or later remission but were ineligible for stem‑cell transplant. GPS treatment produced a median overall survival of 24 months versus 14.7 months in the control arm, with a hazard ratio of 0.59 and a statistically significant p‑value of 0.035. No new safety signals were reported, and the vaccine was generally well tolerated. The results satisfy the primary endpoint of overall survival, a key metric for AML therapies.

Regulatory Path Forward

SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy following the trial outcome. The company aims to submit a BLA in early 2027, which would initiate formal regulatory review. The positive data also strengthen the company’s narrative for potential commercial launch, though approval is not yet secured. Investors are watching FDA discussions closely, as they will determine the timing of the next milestone.

Pipeline and Market Context

Beyond GPS, SELLAS is advancing SLS009, a CDK9 inhibitor under investigation for AML. Preliminary Phase 2 data for SLS009 were expected in Q4 2026, offering another potential catalyst. The stock’s recent surge reflects a broader trend of biotech companies rallying on clinical breakthroughs, and it has drawn attention from both institutional and retail investors. Technical analysis points to a resistance zone around $24–$25; a sustained move above this level could further boost momentum.

What to Watch Next

Key developments to monitor include the company’s meeting with the FDA, any updates on the accelerated filing pathway, and the release of detailed Phase 3 data. Investors should also watch for the first quarterly earnings report, which will provide insight into the company’s financial health and pipeline progress.

Sources

  • Tokenpost: SELLAS Life Sciences Group Begins $150 Million Stock Offering
  • Coinpedia: SLS Stock Soars More Than 200% After Phase 3 Cancer Vaccine Success: What’s Next for SELLAS Life Sciences?

Not financial advice. Crypto assets are volatile and you can lose money. Read our Financial Risk Disclosure.

SELLASAMLFDAPhase 3VaccineAsia
Newsletter

Get the BitcoinEast Daily

Top crypto news, analysis, and market insights, delivered every day.